Income Statement Applied Therapeutics, Inc.
Stocks
APLT
US03828A1016
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-02-02 EST
|
5-day change | 1st Jan Change | ||
| 0.1030 USD | +0.19% |
|
-.--% | +3.00% |
| 02-03 | Cycle Group Holdings Limited completed the acquisition of Applied Therapeutics, Inc. for approximately $14.3 million. | CI |
| 02-03 | Applied Therapeutics, Inc. Announces Management Changes | CI |
| Fiscal Period: December | 2017 (USD) | 2018 (USD) | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|---|---|---|
Revenues | - | - | - | 9.99M | 455K | |||
Total Revenues | - | - | - | 9.99M | 455K | |||
Cost of Goods Sold, Total | - | - | - | 53.9M | 48.74M | |||
Gross Profit | - | - | - | -43.91M | -48.29M | |||
Selling General & Admin Expenses, Total | 32.68M | 43.05M | 27.32M | 20.62M | 56.01M | |||
R&D Expenses | 61.79M | 62.57M | 55.63M | - | - | |||
Other Operating Expenses, Total | 94.47M | 106M | 82.95M | 20.62M | 56.01M | |||
Operating Income | -94.47M | -106M | -82.95M | -64.54M | -104M | |||
Interest Expense, Total | - | - | - | - | - | |||
Interest And Investment Income | 559K | 555K | 685K | 1.37M | 3.53M | |||
Net Interest Expenses | 559K | 555K | 685K | 1.37M | 3.53M | |||
Other Non Operating Income (Expenses) | - | - | -66K | -56.57M | -4.78M | |||
EBT, Excl. Unusual Items | -93.91M | -105M | -82.33M | -120M | -106M | |||
Gain (Loss) On Sale Of Investments | -54K | -521K | -177K | -27K | -77K | |||
Other Unusual Items | - | - | - | - | - | |||
EBT, Incl. Unusual Items | -93.96M | -106M | -82.51M | -120M | -106M | |||
Earnings From Continuing Operations | -93.96M | -106M | -82.51M | -120M | -106M | |||
Net Income to Company | -93.96M | -106M | -82.51M | -120M | -106M | |||
Net Income - (IS) | -93.96M | -106M | -82.51M | -120M | -106M | |||
Net Income to Common Incl Extra Items | -93.96M | -106M | -82.51M | -120M | -106M | |||
Net Income to Common Excl. Extra Items | -93.96M | -106M | -82.51M | -120M | -106M | |||
Per Share Items | ||||||||
Net EPS - Basic | -4.28 | -4.12 | -2.18 | -1.42 | -0.76 | |||
Basic EPS - Continuing Operations | -4.28 | -4.12 | -2.18 | -1.42 | -0.76 | |||
Basic Weighted Average Shares Outstanding | 21.97M | 25.6M | 37.83M | 84.24M | 140M | |||
Net EPS - Diluted | -4.28 | -4.12 | -2.18 | -1.42 | -0.76 | |||
Diluted EPS - Continuing Operations | -4.28 | -4.12 | -2.18 | -1.42 | -0.76 | |||
Diluted Weighted Average Shares Outstanding | 21.97M | 25.6M | 37.83M | 84.24M | 140M | |||
Normalized Basic EPS | -2.67 | -2.57 | -1.36 | -0.89 | -0.47 | |||
Normalized Diluted EPS | -2.67 | -2.57 | -1.36 | -0.89 | -0.47 | |||
Supplemental Items | ||||||||
EBITDA | - | - | -82.95M | -64.53M | -104M | |||
EBITA | -94.47M | -106M | -82.95M | -64.54M | -104M | |||
EBIT | -94.47M | -106M | -82.95M | -64.54M | -104M | |||
EBITDAR | - | - | -82.46M | -64.03M | -104M | |||
Total Revenues (As Reported) | - | - | - | 9.99M | 455K | |||
Normalized Net Income | -58.69M | -65.66M | -51.46M | -74.84M | -65.97M | |||
Supplemental Operating Expense Items | ||||||||
General and Administrative Expenses | 32.19M | 42.54M | 26.83M | 20.12M | 55.46M | |||
Research And Development Expense From Footnotes | 61.79M | 62.57M | 55.63M | 53.9M | 48.74M | |||
Net Rental Expense, Total | 487K | 505K | 489K | 505K | 549K | |||
Stock-Based Comp., COGS (Total) | - | - | - | 3M | 7.34M | |||
Stock-Based Comp., R&D Exp. (Total) | 2.58M | 2.76M | 3.62M | - | - | |||
Stock-Based Comp., G&A Exp. (Total) | 5.45M | 8.42M | 5.54M | 4.36M | 8.23M | |||
Total Stock-Based Compensation | 8.03M | 11.18M | 9.16M | 7.36M | 15.57M |
- Stock Market
- Stocks
- APLT Stock
- Financials Applied Therapeutics, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
